Navigation Links
Ondine Biopharma Announces Sinuwave Technologies Spinout

Ondine Biopharma Corporation, a medical technology company developing photodisinfection based products, today announced its intention to establish a wholly owned subsidiary, “Sinuwave Technologies Corporation”, dedicated to the development and commercialization of photodisinfection based products that address the chronic sinusitis market. The subsidiary will license technology developed by Ondine Biopharma over the past ten years and will leverage product development and clinical and regulatory experiences of the Ondine Biopharma and Advanced Photodynamic Therapy teams.

(Vocus) June 30, 2010 -- Ondine Biopharma Corporation (the "Company" or "Ondine") (TSX:OBP)(AIM:OBP) a medical technology company developing photodisinfection based products, today announced its intention to establish a wholly owned subsidiary, "Sinuwave Technologies Corporation", dedicated to the development and commercialization of photodisinfection based products that address the chronic sinusitis market. The subsidiary will license all relevant Ondine intellectual property and know-how for this application, including technology internally developed over the past ten years and technology obtained in Ondine's December 2009 acquisition of Advanced Photodynamic Technologies Inc. ("APT"). Sinuwave Technologies will leverage the product development, clinical and regulatory experiences of both the Ondine and APT teams.

"We believe the powerful antimicrobial and anti-inflammatory benefits of Ondine's photodisinfection technology have the potential to provide substantial relief to persons who suffer from chronic sinusitis," says Carolyn Cross, Chairman & CEO of Ondine Biopharma Corporation. "Over 43 million people in North America suffer from sinusitis. There are over 450,000 patients for whom sinus surgeries and antibiotics have been unsuccessful. We believe that we can apply our expertise as global leaders in photodisinfection to address this large unmet patient need."

About Ondine Biopharma Corporation

Ondine is developing non-antibiotic therapies for the treatment of a broad spectrum of bacterial, fungal and viral infections. The Company is focused on developing leading edge products utilizing its patented light-activated technology. Photodisinfection provides broad-spectrum antimicrobial efficacy without encouraging the formation and spread of antibiotic resistance. The Company is based in Vancouver, British Columbia, Canada, with a research and development laboratory in Bothell, Washington, USA.

For additional information, please visit and

Forward-Looking Statements:

Certain statements contained in this release containing words like "believe", "intend", "may", "expect" and other similar expressions, are forward-looking statements that involve a number of risks and uncertainties. Factors that could cause actual results to differ materially from those projected in the Company's forward-looking statements include the following: market acceptance of our technologies and products; our ability to obtain financing; our financial and technical resources relative to those of our competitors; our ability to keep up with rapid technological change; government regulation of our technologies; our ability to enforce our intellectual property rights and protect our proprietary technologies; the ability to obtain and develop partnership opportunities; the timing of commercial product launches; the ability to achieve key technical milestones in key products and other risk factors identified from time to time in the Company's public filings.

The TSX Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this release.

For further information please contact:

Carolyn Cross
Chairman and
Chief Executive Officer
Ondine Biopharma Corporation
(604) 669-0555

Canaccord Genuity Limited, Nominated Adviser
Nominated Adviser
Ryan Gaffney
+4420 7050 6500


Read the full story at

Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved  

Related medicine news :

1. Ondine Biopharma CEO Nominated for Manning Innovation Award
2. Therapure Biopharma Inc. and Akorn, Inc. Announce Strategic Supply Contract
3. Therapure Biopharma Inc. signs multi-year manufacturing agreement with LFB Biomedicaments
4. PDL BioPharma Announces Two $0.50 Dividends in 2010
5. Therapure Biopharma Inc. Commissions its Commercial-Scale Lyophilizer
6. Securities Class Action Filed by Shepherd, Finkelman, Miller & Shah, LLP on Behalf of Hemispherx Biopharma Securities Purchasers Between February 18, 2009 and November 2, 2009
7. Therapure Biopharma Inc. and YM BioSciences Inc. Announce Partnership
8. BioProcess International Launches a New and Improved Website for Biopharmaceutical Managers and Scientists
9. Seven More Biopharmaceutical Research Companies Join PhRMA
10. Microbix and Therapure Biopharma Form Partnership to Expand Water-Based Supplies to the Pharma Industry
11. Therapure Biopharma Inc. signs fill/finish contract with Kane Biotech Inc.
Post Your Comments:
Related Image:
Ondine Biopharma Announces Sinuwave Technologies Spinout
(Date:10/13/2017)... , ... October 13, 2017 , ... Lori R. Somekh, ... member of ElderCounsel, a national organization of elder law and special needs planning attorneys. ... and rules. It also provides a forum to network with elder law attorneys nationwide,” ...
(Date:10/13/2017)... ... October 13, 2017 , ... Global Healthcare Management’s 4th Annual ... in Milford, NJ. This free event, sponsored by Global Healthcare Management’s CEO, Jon ... fun run is geared towards children of all ages; it is a non-competitive, non-timed ...
(Date:10/13/2017)... ... ... “America On The Brink”: the Christian history of the United States and the loss ... author, William Nowers. Captain Nowers and his wife, Millie, have six children, ten ... the Navy. Following his career as a naval aviator and carrier pilot, he ...
(Date:10/12/2017)... Fla. (PRWEB) , ... October 12, 2017 , ... IsoComforter, ... therapy products, announced today the introduction of an innovative new design of the shoulder ... pad so you get maximum comfort while controlling your pain while using cold therapy. ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... HMP ... the recipient of a 2017 Folio Magazine Eddie Digital Award for ‘Best B-to-B Healthcare ... City on October 11, 2017. , The annual award competition recognizes editorial and design ...
Breaking Medicine News(10 mins):
(Date:10/11/2017)... 2017  True Health, a leader in integrated ... during National Breast Cancer Awareness month to educate ... Research recently published ... more than 10 million American women are at ... or BRCA2 and have not had testing. These mutations ...
(Date:10/10/2017)... 2017   West Pharmaceutical Services, Inc. (NYSE: ... drug administration, today shared the results of a study ... the intradermal administration of polio vaccines. The study results ... May 2017 by Dr. Ondrej Mach , Clinical ... Organization (WHO), and recently published in the journal ...
(Date:10/4/2017)... South Korea , Oct. 4, 2017  South ... its next-generation CPR training aide "cprCUBE" on Kickstarter. The ... chest compression during cardiac arrests with better efficiency compared ... It also offers real-time feedback on efficacy of the ... The crowdfunding campaign has a goal to raise $5,000. ...
Breaking Medicine Technology: